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Psychosis is a frequent nonmotor complication in Parkinson’s disease (PD), characterized by a broad phenomenology and likely
due to a variety of intrinsic (i.e., PD-related) and extrinsic factors. Safe and eﬀective therapies are greatly needed as PD psychosis
contributes signiﬁcantly to morbidity, mortality, nursing home placement, and quality of life. Novel research strategies focused
on understanding the pharmacology and pathophysiology of PD psychosis, utilizing translational research including animal
models,genetics,andneuroimaging,andevenlookingbeyondthedopaminesystemmayfurthertherapeuticadvances.Thisreview
discusses new research strategies regarding the neurobiology and treatment of PD psychosis and several associated challenges.
1.Introduction
Psychosis is a frequent nonmotor complication of Parkin-
son’s disease (PD) [1–3]. Psychotic symptoms in PD
manifest predominantly as hallucinations and delusions,
although recently revised criteria for PD psychosis extend
the spectrum to include illusions, a false sense of presence,
hallucinations, and delusions [4]. These neuropsychiatric
phenomena likely stem from a combination of drug-related
(i.e., exogenous or extrinsic) factors and PD-related (i.e.,
endogenous or intrinsic) complications, although the exact
pathophysiology of PD psychosis is unknown. Improved
treatments for PD psychosis are greatly needed since hallu-
cinations and delusions are important contributors to mor-
bidity, mortality, nursing home placement, and quality of life
[5–7]. To date, many clinical research trials for antipsychotic
medicationsinPDhavebeenaﬀectedbyissuesoftrialdesign,
medication side eﬀects, and negative outcomes. As such, the
goal of optimally designed clinical trials with eﬀective and
safe medications presents a challenge. Use of animal models
or biomarkers (e.g., genetic or neuroimaging) may provide
additional and complementary ways to advance treatments
for PD psychosis. Thus, the aim of this review is to discuss
new research strategies regarding PD psychosis and their
associated challenges. This review will highlight research
on nondopaminergic substrates, comorbid neuropsychiatric
features often associated with PD psychosis and the potential
roles for integrating in vivo neuroimaging, genetic risk
factors, and animal models in studying PD psychosis, and
lastly discuss challenges of medication trials.
Dopaminergic medications have been well recognized to
induce psychosis in PD by stimulating or inducing hyper-
sensitivity of mesocorticolimbic dopamine receptors [8–10].
Virtually all classes of anti-parkinsonian medications may
produce psychosis in PD. Some studies suggest particular
susceptibility with dopamine agonists compared to levodopa
[11–15] and with anticholinergics especially in elderly PD
patients [16]. While dopaminergic medications contribute
to PD psychosis, exploration of other extrinsic and intrinsic
factors is needed to advance our understanding of and
our treatments for PD psychosis. Intrinsic or PD-related
factors that may contribute to PD psychosis include abnor-
malities in the visual system; levels of visual dysfunction
range from ocular pathology and retinal dopamine loss,
impaired visual acuity and color or contrast discrimination,
to disturbed attentional and visuospatial processing and
abnormal cortical activation patterns [17–22]. Other factors,
often noted in epidemiological studies, encompass clinical2 Parkinson’s Disease
riskfactorssuchasage,PDdurationandseverity,depression,
cognitive impairment and dementia, and sleep disturbances
[2, 3]. PD hallucinators exhibit worse cognitive function
overall including executive, attentional, and visuospatial
abilities [23–26] and also have been observed to have greater
sleep disturbances and REM behavior disorder [27–33].
Neuroimaging studies also suggest that there are distinct
structural, functional, and metabolic abnormalities in PD
hallucinators [20, 22, 34–40]. This review highlights several
of these risk factors or comorbid neuropsychiatric features
associated with PD psychosis as potential avenues for
selective therapeutic strategies.
2. Beyond Dopamine: Other Neurochemical
SubstratesandNeuropsychiatricFeatures
AssociatedwithPDPsychosis
While nondopaminergic substrates have long been thought
to play a role in PD psychosis, they form the basis for
several current therapeutic strategies of PD psychosis and
merit continued attention. This section will review the
importance of the cholinergic and serotonergic systems and
other neuropsychiatric features commonly associated with
PD psychosis.
2.1. Cholinergic System. The role of the central cholinergic
system in PD psychosis is underscored by its involvement
in cognition and sleep, two neuropsychiatric areas that
are intricately linked to hallucinations and delusions in
PD. PD dementia and dementia with Lewy bodies exhibit
pronounced frontal cortical denervation due to disrup-
tion of the ascending cholinergic transmitter system and
degeneration of central cholinergic structures involved in
attention, cognition, and REM sleep such as the nucleus
basalis of Meynert and pedunculopontine nucleus [41, 42].
In addition, pharmacological interventions with anticholin-
ergic medications such as scopolamine or trihexyphenidyl
are recognized to cause confusion in PD [16, 43].
Cognitive impairment and dementia have been asso-
ciated with PD psychosis in many studies [2, 23, 44].
Presence of hallucinations is a signiﬁcant predictor of
dementia in PD, and cognitive decline is faster in those
PD patients with hallucinations [45, 46]. More recently,
clinical trials in PD dementia, Alzheimer’s disease, and
dementia with Lewy bodies have demonstrated a positive
eﬀect of cholinesterase inhibitors on hallucinations and
psychosis [47]. A subanalysis of 188 PD hallucinators from
a large, multicenter, double-blind, placebo-controlled trial
of rivastigmine in mild to moderate PD dementia was
conducted [47], and rivastigmine-placebo diﬀerences for
severalmeasures(i.e.,ADAS-cog,ADCS-CGIC,andNPI-10)
were found to be signiﬁcantly larger in the hallucinators than
in the nonhallucinators. Greater therapeutic beneﬁt could be
potentially derived from the use of cholinesterase inhibitors
in select PD patients with dementia and hallucinations
[48].
Sleep disturbances are frequent in PD patients, including
those with hallucinations. Several studies suggest that PD
hallucinations are related to sleep fragmentation and altered
dream phenomena, but whether this represents a stepwise
pattern or “continuum” [27], distinct but related factors
[49], or predictors of future hallucinations [49, 50]i s
uncertain. Compared to PD patients without hallucinations,
the hallucinators have decreased sleep eﬃciency, total REM
sleep time, and REM sleep percentage on polysomnography
[51–53] and altered circadian rest-activity rhythms on
actigraphy [33]. These disturbances in sleep architecture,
REM sleep, and circadian patterns suggest involvement of
brainstem and hypothalamic sleep centers with complex
interactions among neurotransmitters such as acetylcholine,
serotonin, noradrenaline, histamine, GABA, hypocretin as
well as dopamine [54]. Few PD studies, to date, have assessed
the eﬀect of antipsychotics on sleep and hallucinations. In
a small, pilot study, Fernandez et al. assessed quetiapine’s
eﬃcacy in improving visual hallucinations and its eﬀect on
sleepusingpolysomnography[55].Nosigniﬁcantdiﬀerences
in REM duration were found in either the quetiapine or
placebogroups,althoughthesamplesizewassmallandstudy
completion rate was low. The control of sleep-wake patterns
integrates many neurotransmitters involved in PD, and sleep
and circadian disturbances may represent important targets
not only for PD sleep but also for hallucinations.
2.2. Serotonergic System. The serotonin (5HT) system has
been implicated in PD psychosis as well as in mood
disturbances such as depression and anxiety. While an
imbalance in serotonin and dopamine contributing to PD
psychosis was suggested as early as 1975 by Birkmayer and
Riederer[56],thedevelopmentofantipsychoticswithgreater
serotonergic aﬃnity including 5HT-2a receptors, such as
second-generation antipsychotics, clozapine, or quetiapine,
has brought renewed attention to the serotonin system.
In PD, there is an extensive loss of serotonergic raphe
neurons and a reduction of serotonergic projections to the
frontal cortex, temporal cortex, and putamen. Complex
interactions among dopamine, serotonin, acetylcholine, and
norepinephrine, among others occur. Dopamine adminis-
tration may lead to hyperstimulation of 5HT-2a receptors
that aﬀects glutamatergic-modulated activity of dopamine
neurons in the ventral tegmental area; this may lead to exci-
tation of the limbic system and inhibition of the prefrontal
cortex [9], areas important to cognitive and behavioral
processes. Additional evidence for serotonin’s contribution
to PD psychosis stems from a recent positron emission
tomography study using a selective 5HT-2a receptor ligand,
[18F]-setoperone, in 7 nondemented PD patients with visual
hallucinationscomparedto7age-matchedPDwithoutvisual
hallucinations [57]. In this pilot study, the PD hallucinators
had increased 5HT-2a receptor binding in multiple brain
regions including the ventral visual pathway, bilateral dor-
solateral prefrontal cortex, medial orbitofrontal cortex, and
insula, suggesting alterations in pathways mediating visual
and cognitive processing and a role for 5HT-2a in PD
hallucinations. Furthermore, abnormalities in brain 5HT2a
receptors were found in a recent postmortem tissue study
[58]; increased [3H]-ketanserin binding in the inferolateral
temporal cortex was found in PD patients who had visualParkinson’s Disease 3
hallucinations, compared to those who did not, though
potential confounders such as dementia, mood disorders,
medications, and disease duration await further study.
PD psychosis and mood disorders both involve the
serotonin system, and this relationship has been explored
in some studies. Several reports demonstrate positive eﬀects
of antidepressants on PD psychosis [59–61]. However, the
use of antidepressants in PD psychosis has been historically
controversial as there also have been a few case reports of
antidepressants (e.g., bupropion, ﬂuoxetine, and mirtazap-
ine) exacerbating PD psychosis [62–64]. The worsening of
psychosis has been attributed to enhanced dopamine release
by stimulation of serotonin receptors by the antidepressants.
Despite this, antidepressants, particularly serotonin reuptake
inhibitors (SSRIs) or serotonin-norepinephrine reuptake
inhibitors (SNRIs), have been widely used in mood dis-
turbances in PD without clear evidence of triggering or
aggravating psychosis. In a review of depressed PD patients
from our movement disorders clinic, the addition of SSRIs
didnotexacerbatehallucinationrisk,asmeasuredbychanges
in thought disorder scores from the Uniﬁed Parkinson’s
disease Rating Scale, in depressed PD patients on stable
dopaminergic medication regimens [65].
Several case reports and a small case series have sug-
gested a beneﬁcial eﬀect of antidepressants in PD psychosis,
particularly those patients with coexisting mood disorders
[59–61]. Voon et al. reported a series of 10 PD patients
with psychotic symptoms and comorbid depression or
anxiety who were treated with antidepressants (citalopram
or venlafaxine) and had pre- and posttreatment evaluations
of their psychosis and mood disorders, in a prospective
but unblinded fashion. Psychotic symptoms improved in
8/10 patients when antidepressants were used either as
monotherapy or as adjuncts to baseline antipsychotics (in
2/10). Proposed mechanisms for the positive eﬀects of
antidepressants on PD psychosis included the following: (1)
improvement in underlying depression which could have
exacerbated psychotic symptoms; (2) increased serotonergic
tone since low serotonin levels can be associated with
depression, aggression, and impulsivity; (3) restoration of
serotonin-dopamine imbalance; (4) decrease in the upregu-
lationofpostsynapticserotoninreceptorsduetoraphenuclei
degeneration;or(5)REMsuppressionbytheantidepressants
[60, 61, 66]. Limitations, however, included a small, open-
label design, disease-related, and treatment-related diﬀer-
ences among patients and heterogeneity of hallucinations,
psychosis, and psychiatric diagnoses.
Despite the limitations and lack of controlled stud-
ies of antidepressants and PD psychosis, these reports
raise questions regarding interactions between serotonin-
dopamine systems, the relationship between hallucinations,
psychosis and mood disorders in PD, and the occurrence
of psychotic depression in PD and how this diﬀers from
psychotic depression in other populations. Well-designed,
controlled studies of select SSRIs or other antidepressants
will be needed to determine if they may be an appropriate
pharmacological strategy for treating psychosis in PD with
or without comorbid mood disorders. Treatment rationales
that incorporate comorbid neuropsychiatric phenomena
such as cognition, sleep, and mood may provide alternative
treatment strategies for PD psychosis.
3. Neuroimaging: AWindow intoPD Psychosis
Neuroimaging studies permit in vivo investigations of brain
alterations in PD patients with hallucinations. Techniques
utilized include structural magnetic resonance imaging
(MRI) to assess gray matter atrophy, functional MRI to
examine activation patterns, and perfusion scans to inves-
tigate changes in regional cerebral blood ﬂow or glucose
metabolism. The neuroimaging studies of PD and visual hal-
lucinations provide clues as to underlying neuroanatomical
substrates and pathophysiology of PD hallucinations.
3.1. Structural MRI. Structural MRI studies of visual hal-
lucinations in PD have examined regional and global brain
atrophy patterns. Using whole-brain voxel-based mophom-
etry (VBM) to study cerebral atrophy, Ram´ ırez-Ruiz et al.
found signiﬁcantly reduced gray matter volume in the
lingual gyrus and superior parietal lobe, regions involved
in higher-order visual processing, in the PD hallucinators,
compared to nonhallucinating PD and healthy controls
[40]. In another study, hippocampal atrophy was detected
in 3 groups of PD patients (i.e., PD with dementia,
nondemented PD with hallucinations, and nondemented
PD without hallucinations), compared to healthy controls,
at rates of 78%, 31%, and 26%, respectively, [35]. The
nondemented,hallucinatingPDgroupexhibitedgreatergray
matter reduction in the hippocampal head, an area asso-
ciated with speciﬁc memory functions. Of note, although
the hallucinating PD patients were not demented, they
performed worse on neuropsychological tests. The same
authors studied 12 nondemented, hallucinating PD patients,
compared to 14 PD patients without hallucinations, and
12 healthy controls for a mean 29.91 (5.74) months with
MRI (VBM analyses) and neuropsychological tests [67].
At follow-up, 75% of the hallucinating PD had developed
dementia. The PD hallucinators demonstrated widespread
limbic, paralimbic and neocortical gray matter loss, regions
also abnormal in PD dementia. These studies support
regional neuroanatomical changes and clinical links between
hallucinations and cognitive impairment in PD.
3.2. Functional MRI. Functional MRI (fMRI) studies in
PD patients with hallucinations demonstrate altered corti-
cal activation patterns compared to PD nonhallucinators.
Stebbins et al. studied 12 PD patients with chronic visual
hallucinations, matched for age, disease duration, and
dopaminergic drug exposure to PD patients who had never
hallucinated using two visual stimulation fMRI paradigms
(i.e., stroboscopic and kinematic). The PD hallucinators had
signiﬁcantlygreaterfrontalandsubcorticalactivationtoboth
visual stimulation paradigms and decreased cerebral acti-
vation in occipital, parietal, and temporal-parietal regions,
compared to the nonhallucinators [22], thereby suggesting a
disruption in normal visual processing mechanisms in the
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(e.g., face recognition task) revealed signiﬁcant reductions
in right prefrontal areas including the inferior, superior,
and middle frontal gyrus and anterior cingulate gyrus in
PD hallucinators to the face stimulus, compared to non-
hallucinating PD and healthy controls [68]. These ﬁndings
suggest disruptions between anterior (e.g., frontal) and
posterior (e.g., parietal, temporal, occipital) regions that are
important in processing visual stimuli and impaired abilities
to distinguish relevant from irrelevant visual information in
PD hallucinators. Further evidence for impaired “bottom-
up”visualprocessinginhallucinatingPDcomesfromafMRI
study by Meppelink et al. in which several seconds prior to
image recognition task, the nondemented, hallucinating PD
patients showed reduced activation of the lateral occipital
cortex and extrastriate temporal visual cortices, compared to
nonhallucinating PD and healthy controls [69]. In contrast
to other studies, however, the authors did not ﬁnd increased
“top-down” frontal activation in their sample.
3.3. Metabolic Studies. Decreased perfusion or glucose
metabolism in predominantly posterior brain regions has
been reported in PD hallucinators using single photon
emission computed tomography (SPECT) or positron emis-
sion tomography (PET) modalities. Using 99mTc-HMPAO
SPECT, Okada et al. found decreased cerebral blood ﬂow to
the left temporal lobe and temporal-occipital lobe regions
in hallucinating PD patients [70]. In one [123I] IMP SPECT
study, hypoperfusion in the right fusiform gyrus but hyper-
perfusion in the right superior and middle temporal gyri was
found in PD hallucinators, when covarying for MMSE score
and PD duration [71], suggesting importance of the visual
ventral stream. Also using [123I] IMP SPECT scans, Matsui
et al. found reduced perfusion in bilateral inferior parietal
lobules, inferior temporal gyrus, precuneus gyrus, and
occipital cortex in 31 PD patients with visual hallucinations,
compared to 39 without hallucinations [38]. Decreased
metabolismintemporal-occipital-parietalregionswasfound
in 8 PD hallucinators compared to 11 nonhallucinators
with [18F] FDG-PET [34]. Similar to some fMRI results
whichindicatedisruptionsinfrontalandposterioractivation
patterns, Nagano-Saito et al. found greater regional cerebral
glucose metabolic rates in frontal regions, especially the
left superior frontal gyrus, in 8 nondemented, PD patients
withvisualhallucinations,comparedtononhallucinatingPD
and healthy controls, using [18F] FDG-PET [72]. Overall,
neuroimaging studies using diﬀerent modalities emphasize
the relationship between frontal and posterior brain regions,
visual and cognitive processing, and pathogenesis of PD
hallucinations.
3.4. Challenges. While the neuroimaging studies allow for an
in vivo assessment of the brain in PD hallucinators, there are
several limitations, confounders, and challenges. Acquiring
neuroimaging studies in PD patients can be diﬃcult due to
issues of motor ﬂuctuations, tremor or dyskinesias, impaired
attention, dementia, and active psychosis. Moreover, fMRI
studies in particular can be aﬀected by factors such as
impaired attention, motivation, and cognition; medication
eﬀects including antipsychotics; and visual acuity deﬁcits.
Although interesting, imaging PD patients while they are
actively hallucinating or delusional could pose certain chal-
lenges. The majority of the neuroimaging studies, to date,
have focused on chronic visual hallucinations, and thus,
whether the ﬁndings reﬂect the pathogenesis of delusions
or hallucinations in other sensory modalities is not known.
Additionally, comorbid neuropsychiatric issues such as cog-
nitive impairment, even mild, and depression may share
neuroanatomical substrates (e.g., temporal lobe) and could
inﬂuence interpretations of studies. Despite these challenges,
studies using diﬀerent neuroimaging modalities, applied
individuallyorincombination,havethepotentialtoenhance
our understanding of the pathogenesis of PD psychosis.
4. GeneticRisk Factorsfor PDPsychosis
Besides clinical risk factors such as age, PD duration and
severity, depression, cognitive impairment and dementia,
and sleep disturbances [2, 3], genetic factors may be involved
inthedevelopmentofPDpsychosis.Geneticpolymorphisms
that aﬀect levodopa or dopamine-agonist metabolism have
been shown to play a role in other medication-related
complications such as dyskinesias or motor ﬂuctuations
[73, 74]. With the growing ﬁeld of pharmacogenetics,
interindividual diﬀerences in medication responses due to
underlying genetic polymorphisms may become increasingly
important in drug development, evaluation of drug eﬃcacy
and toxicity, and ultimately, individualized patient care.
Various genetic polymorphisms have been considered
regarding increased risk of psychosis in PD. This section
will discuss several studies of genetic polymorphisms in the
dopamine, serotonin, and cholecystokinin systems as well as
apolipoprotein E (APOE) 4 allele status in PD hallucinators.
In general, many of the studies have yielded conﬂicting
results, and thus, the relationship between genetic inter-
individual variability and disease-related complications of
PD awaits further exploration. Diﬀerences in methodologies
and ethnic backgrounds of subjects may be critical contribu-
tions to the negative or conﬂicting study results.
4.1. Dopaminergic System. Investigations of the dopamin-
ergic system have included D1 class receptors (DRD1 and
DRD5), D2 class receptors (DRD2, DRD3, DRD4), as well as
the dopamine transporter gene (DAT). Makoﬀ et al. studied
polymorphismsofDRD2(−141C/delinthepromoterregion
and TaqIA restriction fragment length polymorphism C > T)
and DRD3 (Ser9Gly) in hallucinating and nonhallucinating
white PD patients [75]. No association of these DRD2 or
DRD3 polymorphisms was found when comparing the 84
hallucinatorstothe71nonhallucinatorsasagroup.However,
an association was found with the C allele of the TaqIA
polymorphism to DRD2 and late-onset hallucinators (i.e.,
those PD patients who developed hallucinations after 5 years
of disease). The nonhallucinating controls for the whole
group were matched for disease duration, age at disease
onset, duration of dopaminergic therapy, and gender, but
not medication doses or classes of dopaminergic agents.Parkinson’s Disease 5
In a case-control study of 44 matched pairs of white PD
patients with and without chronic hallucinations, Goetz
et al. assayed dopamine receptor genes, including DRD1,
DRD2, and DRD3 [76]. They found no signiﬁcant diﬀerence
in allele frequencies or distribution of genotypes between
hallucinating and nonhallucinating PD patients for DRD1
and DRD3, although the DRD3 2 allele had a borderline
increased frequency in hallucinators (P = .047). Similarly, a
case-control study of Chinese PD patients with and without
hallucinations did not ﬁnd an association at DRD2 (TaqIA,
32806 C > T), DRD3 (Ser9Gly and Msp1), or DRD5 (978
T > C) [77]. Of note, the DRD2 polymorphism has been
associated with dyskinesias and wearing oﬀ in PD [78, 79].
The positive association of the DRD2 polymorphism with
dyskinesias and wearing oﬀ but not with hallucinations
suggests that the underlying pathogenesis of neuropsychi-
atric and motor complications in PD diﬀers. Alternatively,
polymorphisms in the dopamine receptor genes may be
minimally involved in PD psychosis, given the negative
results from the three studies described.
Other studies have focused on the dopamine transporter
gene (DAT) since the dopamine transporter controls the
presynaptic reuptake of dopamine. In some reports, a 40bp
variable number of tandem repeat (VNTR) polymorphism
in the 3 -untranslated region of the DAT gene has been
associated with psychiatric conditions such as attention-
deﬁcithyperactivitydisorder,alcoholism,andschizophrenia.
In a study of white PD patients, Kaiser et al. examined the
VNTR polymorphism of the DAT gene, along with DRD2,
DRD3, and DRD4 polymorphisms, and found that the 9 ×
40bp VNTR allele of the DAT gene was more frequently
present in those levodopa-treated PD patients with psychosis
or dyskinesias, compared to nonaﬀected patients (odds ratio
2.6; 95% CI: 1.3–5.3; P = .008 and odds ratio 2.5; 95% CI:
1.3–4.7; P = .007, respectively, for psychosis and dyskinesia)
[80]. The ﬁnding of diﬀerences in the 9-copy allele of the
DAT VNTR, however, was not conﬁrmed in either a case-
control study of Chinese PD patients with and without
hallucinations [77] or in our case-control study of white PD
patients with and without hallucinations [81]. Larger studies
of diﬀerent ethnic populations are needed to further study
the role of the DAT gene and dopaminergic system in PD
psychosis.
4.2. Serotoninergic System. Polymorphisms in the serotonin
(5HT) transporter gene have been thought to inﬂuence
anxietyanddepressionbyalteringserotonergictone[82,83].
The serotonin transporter gene, similar to the dopamine
transporter gene, plays a critical role in the termination
of 5HT transmission by controlling presynaptic reuptake
[84]. Two functional polymorphisms in the serotonin trans-
porter gene have been identiﬁed and contribute to protein
expression. These include a promoter VNTR (short, long
alleles) and intron 2 VNTR (9, 10, 11, 12 alleles). Less
eﬃcient transcription and decreased reuptake results from
a deletion (short [s] allele compared to long [l] allele)
or presence of 10-copy allele in intron 2 VNTR in the
transporter gene. Some studies have reported a signiﬁcant
association of the s/s and l/s genotypes and anxiety-related
traits in the general population as well as in depressed or
anxious PD patients [82]. In a study of 32 genotyped PD
patients who were administered the Hamilton Depression
and Anxiety scales, those PD patients who had the short
allele had signiﬁcantly higher scores on the depression and
anxiety measures [85]. For the VNTR element in intron 2
of the serotonin transporter gene in which four variants
may occur, increased frequency of the 9-copy allele has
been reported in aﬀective disorders [83]. However, this
ﬁnding was not conﬁrmed in PD patients with depression
[86]. In our case-control study, we examined these two
serotonin transporter gene polymorphisms in white PD
patients with and without hallucinations but did not ﬁnd
any diﬀerences in allelic or genotypic frequencies of short
or long alleles or intron sequences of the VNTR element
[87]. Thus, the serotonin transporter gene polymorphisms
may have greater association with anxiety and other aﬀective
disorders rather than psychosis, although further study is
needed. Alternatively, since the serotonin system encom-
passes many receptor subtypes, individual receptors rather
than the transporter itself may be associated with psychosis,
as suggested by atypical antipsychotic pharmacology. Kiferle
et al. examined polymorphisms in the 5HT-2a gene (T102C)
as well as the serotonin transporter gene (short, long alleles)
[88]. However, in their nondemented, white PD group, no
signiﬁcant diﬀerences in either polymorphism between PD
patients with and without hallucinations were found.
4.3. Cholecystokinin. Cholecystokinin (CCK), a neuropep-
tide found in both the gut and central nervous system, is
involved in dopaminergic regulation and colocalizes with
dopaminergic neurons. The CCK receptor genes, CCKAR
and CCKBR, have been cloned and sequenced in humans
[89]. Centrally, CCKAR mediates the behavioral actions of
CCK and CCK-stimulated dopamine release in the posterior
nucleus accumbens. In contrast, CCKBR mediates CCK
inhibition of dopamine release in the anterior nucleus
accumbens [90]. The nucleus accumbens, part of the
cortico-striato-thalamo-cortical loop, is associated with the
mesolimbic pathway and behaviors such as reward, pleasure,
and addiction. Due to their role in mesocorticolimbic
circuitry, CCK and its receptors were initially studied in
alcoholism and schizophrenia with auditory hallucinations
and later in PD psychosis.
Studies in Asian PD patients suggest that CCK poly-
morphisms may diﬀer in hallucinating PD patients. Fujii et
al. reported that Japanese PD patients with hallucinations
diﬀered at the CCK −45 C/T locus, with overrepresentation
of CT and TT genotypes in the hallucinators, though this
did not remain signiﬁcant when correcting for multiple
comparisons [91]. Since the C to T transition occurs in
the Sp1-binding cis element of the CCK gene promoter,
mutations at this site might aﬀectpromoter activity and gene
transcription [92]. In a study of Chinese hallucinating and
nonhallucinating PD patients treated with levodopa, the hal-
lucinators signiﬁcantly diﬀered at the CCK −45 C/T locus,
with overrepresentation of the T allele in the hallucinators
[93]. Moreover, there was an almost 6-fold increased risk for6 Parkinson’s Disease
developing hallucinations if the CCK T allele and CCKAR C
allelewerepresentincombination.Inourinvestigationofthe
CCK system in a matched sample of white PD hallucinating
cases and nonhallucinating controls, we did not ﬁnd any
diﬀerence in allele frequencies or genotype distribution for
CCK but detected a trend for an over-representation of the
CCK T allele in hallucinating PD patients (P = .06) [94].
4.4.APOE4. TheAPOE4alleleis recognized asanimportant
genetic risk factor in Alzheimer’s disease but has been
variably reported in PD dementia. Because dementia and
psychosis may coexist, polymorphisms in APOE4 have been
investigated as genetic risk factors for PD hallucinations.
In a study of nondemented PD patients, the APOE4 allele
was present in 13/17 (76%) hallucinators compared to
20/88 (23%) nonhallucinators, remaining signiﬁcant after
adjustment for age, PD severity, treatment duration, lev-
odopa dose, and agonist treatment [95]. Other studies,
however, have failed to replicate these ﬁndings. Whether or
not the APOE4-positive, hallucinating patients subsequently
developed dementia or had coexisting Alzheimer’s disease
pathology is not known. Goetz et al. did not ﬁnd any dif-
ference in APOE4 alleles in their case-control study, despite
the PD hallucinators having lower Mini-mental State exam-
ination scores (mean [SD] for hallucinators 23.7 [5.3] and
nonhallucinators 28.8 [2.4]) [76]. No association between
APOE4 and PD hallucinations was found in a study of 47
autopsy-proven PD patients [96]; in this study, Camicioli et
al. included patients as “hallucinators” if hallucinations were
ever recorded in the charts regardless of persistence or etiol-
ogy.Whileeventransienthallucinationsmaynotbe“benign”
in their course, it remains to be seen whether genetic sus-
ceptibilities diﬀer in PD patients with illusions, intermittent
hallucinations, chronic hallucinations, or delusions.
4.5. Challenges. Conﬂicting results and methodological
issues have complicated the studies of genetic polymor-
phisms and PD hallucinations. Confounding variables that
may inﬂuence these genetic association studies include but
are not limited to small sample sizes, methodological dif-
ferences (case-control studies versus larger population-wide
studies),anddiﬀerencesindemographicorPD-relatedissues
such as age, gender, disease duration, medications, cognitive,
and mood disorders. Moreover, an important consideration
is that genetic polymorphisms vary greatly among diﬀerent
ethnic groups. In addition, it remains possible that some
nonhallucinating patients examined in cross-sectional stud-
ies might convert to hallucinators over time. Longitudinal
follow-up would be necessary to assess conversion risk and
genetic status as a predictor of hallucinations. Nevertheless,
the genetic association studies may prove to be informative
and useful regarding genetic susceptibility, drug develop-
ment, and potentially individualized treatment regimens.
5. AnimalModels of Psychosis
Animal models provide important translational tools by
which to study the neurobiological substrates of disease
and to investigate treatments for speciﬁc disease-related
symptoms. Animal models such as the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine- (MPTP-) lesioned primates and
6-hydroxydopamine- (6-OHDA-) lesioned rodents have
been inﬂuential in studying parkinsonism and levodopa-
induced dyskinesias. However, hallucinations and other
psychotic behavior have been more diﬃcult to study in
animals given the subjective nature of the hallucinatory
experience and the challenge of inferring meaning from an
animal’s behavior. In rodents and primates, amphetamine
and other stimulants (e.g., the glutamate NMDA receptor
antagonists ketamine and phencyclidine) have been long
used as potential models of psychosis or positive symptoms
of schizophrenia due to their ability to stimulate locomotor
activity,producestereotypies,andenhancestriataldopamine
release [97]. In primates treated with chronic amphetamine,
induced movements such as stereotypies and hyperactivity
and behaviors such as hypervigilance, checking, grasping,
and staring may occur [98, 99].
5.1. Studies of Psychosis-Like Behaviors in MPTP-Lesioned
Primates. MPTP-lesionedprimateshavebeennotedtoexpe-
rience abnormal psychomimetic behaviors that are reminis-
cent of the “psychosis-like” behaviors in the amphetamine-
sensitized animals, and these behaviors may have utility in
studying PD psychosis [100, 101]. Fox et al. examined these
phenomena in primates; marmosets treated with MPTP
and housed under controlled conditions were subsequently
exposed, after a stable parkinsonian period, to several
diﬀerent dopaminergic and antipsychotic medications. In
order to quantify the psychosis-like behaviors, the authors
proposed a rating scale with behavioral categories including:
(1) agitation, hyperkinesias; vocalizations; (2) hallucinatory-
like response to apparent nonstimuli, tracking, staring; (3)
obsessive grooming, scratching or grooming repetitively;
and (4) stereotypes, repetitive side-to-side jumping, head
checking movements, purposeless running, and grasping
at the bars [101]. These behaviors, deemed distinct from
dyskinesias, were rated by a blinded observer, in addition
to parkinsonism and dyskinesias, and summed for a total
psychosis-like behavior score.
In a series of experiments, the authors examined re-
sponses to various dopaminergic medications and antipsy-
chotics. Both levodopa and dopaminergic receptor agonists
(pergolide, pramipexole, and ropinirole) induced peak-dose
psychosis-like behavior in the MPTP-lesioned primates as
well as reversed parkinsonian disability, compared to the
vehicle [100]. No diﬀerence in psychosis-like behavior was
observed among the dopaminergic agents. In a companion
study using a similar protocol [101], the authors found
that levodopa produced psychosis-like behavior in the 7
marmosets studied. Of the psychosis-like behaviors exhib-
ited, stereotypies were the most common, and all animals
exhibited staring and tracking behavior (hallucinatory-
like). There was no correlation between severity of dysk-
inesias and psychosis-like behavior in individual ani-
mals with levodopa. Amantadine coadministered with lev-
odopa signiﬁcantly increased total peak-dose psychosis-like
behavior but reduced peak-dose dyskinesias. Psychosis-likeParkinson’s Disease 7
behaviors, particularly stereotypies, were decreased when
haloperidol was coadminstered with levodopa. Not surpris-
ingly, haloperidol, compared to vehicle, worsened parkin-
sonism and reduced dyskinesias. Although quetiapine was
coadministered with levodopa in only 6 animals, results
diﬀered based on dose; signiﬁcant reduction in the total
psychosis-like score was seen in the 1.5mg/kg group but
not the 0.5mg/kg or 4.5mg/kg doses, compared to vehicle.
Clozapine reduced psychosis-like behaviors, compared to
vehicle, with a decrease in hallucinatory-like behavior.
Neither quetiapine nor clozapine worsened parkinsonism or
produced somnolence.
5.2. Challenges. One of the greatest challenges of the animal
models is whether one can infer that the primates’ behaviors
recapitulate the human experiences of hallucinations and
psychosis. However, these dopaminergic-stimulated abnor-
mal behaviors, as distinguished from dyskinesias, may rep-
resent a close approximation of PD neuropsychiatric dis-
turbances and an opportunity to evaluate pathophysiology
and therapeutics for psychosis and heightened dopaminergic
states.
6. Recent Pharmacological Trials and
Challenges of PD Psychosis Trials
Atypical antipsychotics, such as clozapine and quetiapine,
which have greater serotonergic antagonism than dopamine
receptor blockade have been generally favored in the man-
agement of PD psychosis due to the decreased risk of wors-
ened parkinsonism and other extrapyramidal syndromes.
Much of the serotonin eﬀect of these atypical antipsychotics
relates to drug interactions with the 5HT-2a receptors, which
in the central nervous system can be found in the cortex,
basal ganglia (caudate and putamen), and hippocampus
[102]. Interestingly, 5HT-2a antagonists or inverse agonists
including clozapine also have demonstrated improvement
in parkinsonian motor function in primates and humans
[103, 104]. Based on these pharmacological proﬁles, several
atypical antipsychotics acting on the 5HT-2a system, such as
melperone and pimavanserin (ACP-103), have been recently
studied in PD psychosis. The following section will brieﬂy
discuss ﬁndings related to these newer agents and challenges
of PD psychosis trials. Other medications studied in PD
psychosis, including quetiapine, clozapine, among other
atypical antipsychotics, have been the subject of other recent
reviews and are not discussed here [105].
6.1. Melperone. Melperone has been available in some
European countries and in use as an antipsychotic for
schizophrenia for over 10 years. Although a butyrophenone,
melperonehasbeenconsideredanatypicalantipsychoticdue
to its low extrapyramidal symptoms and lack of increase
in plasma prolactin [106, 107]. It is similar to clozapine in
that it also has high 5HT-2a aﬃnity relative to dopamine
(D2) receptor binding aﬃnities. In an open-label trial for
PD psychosis, Barbato et al. assessed the clinical eﬃcacy and
safety of melperone in 30 PD patients with psychosis over
a 24-month period [108]. In 28/30 PD patients, psychotic
symptoms, as measured by the Brief Psychiatric Rating Scale
(BPRS), improved with a mean daily dose of 37.5mg (range
12.5–75mg daily) without worsening motor scores. Doses
were much smaller than those utilized in schizophrenia,
similar to the low clozapine and quetiapine doses used in
PD psychosis. Side eﬀects included hypotension, dizziness,
and sedation (leading to discontinuation by 2 patients).
Based on this study, a multicenter, randomized, double-
blind, placebo-controlled, 10-week, Phase II trial evaluating
the safety and eﬃcacy of melperone in PD psychosis was
conducted in the US and recently ﬁnished. However, to date,
no results have been published in scientiﬁc journals.
6.2. Pimavanserin (ACP-103). Pimavanserin (ACP-103) is a
5HT-2a receptor inverse agonist, which has been recently
investigated in PD psychosis [109, 110]. Although pima-
vanserin (ACP-103) also has some 5HT-2c receptor aﬃnity,
it exhibits about 30-fold greater selectivity for the 5HT-2a
receptor compared to the 5HT-2c receptor [103]. Results
from a multicenter, randomized, double-blind, placebo-
controlled, 28-day, Phase II study to evaluate the tolerability,
safety, and eﬃcacy of pimavanserin in 60 PD patients were
recently published [111]. The study, powered for diﬀerences
in the UPDRS Parts II and III scores, had favorable results
regarding motor function, with no signiﬁcant diﬀerences
observed between drug and placebo groups. In addition,
there were no signiﬁcant diﬀerences in adverse events
between treatment groups. Regarding psychosis outcomes,
the Scale for the Assessment of Positive Symptoms (SAPS)
total domain score was chosen as the primary outcome
measure for eﬃcacy based on its use in the Parkinson’s Study
Group clozapine trial, and a trend for greater improvement
in pimavanserin-treated patients was detected (P = .09,
eﬀect size = 0.52). Analyses of many individual items from
the SAPS and UPDRS psychosis question failed to reveal sig-
niﬁcant diﬀerences between treatment groups; however, the
global ratings for hallucinations and delusions signiﬁcantly
favored the pimavanserin arm. Subsequently, a multicenter,
randomized, double-blind, placebo-controlled, Phase III
trial with a larger sample of PD patients was completed;
reports reveal that although the drug was tolerated in terms
of motor function and side eﬀects, a statistically signiﬁcant
beneﬁt for psychosis measures was not achieved [112]. Of
note, this same compound has been under evaluation in
primate models of levodopa-induced dyskinesias [103]a n d
schizophrenia-related psychosis and insomnia. Since sero-
tonin may inﬂuence sleep architecture, pimavanserin and
similar compounds could also improve sleep maintenance
and quality in those with insomnia [109, 113].
6.3. Challenges. In addition to the pharmacological chal-
lenges of ﬁnding antipsychotics that safely treat PD psy-
chosis without worsening parkinsonism or causing other
adverse eﬀects, there are challenges related conducting the
trials and many issues pertaining to optimal trial design,
inclusion/exclusion criteria, subject recruitment, and study
completion. In 2006, the Quality Standards Subcommittee8 Parkinson’s Disease
of the American Academy of Neurology published a Prac-
tice Parameter report on the evaluation and treatment of
depression, psychosis, and dementia in PD. Of 23 articles on
psychosis treatment in PD patients identiﬁed by the authors,
only four Class I and II articles were accepted for review.
BasedonareviewofthesePDpsychosisstudiesonclozapine,
quetiapine, and olanzapine, the authors concluded that, as
demonstratedbyoneClassIstudy[114](PSG)andoneClass
II study [115], clozapine was probably an eﬀective treatment
for PD psychosis without motor worsening. Clozapine use,
despite its eﬃcacy, is often limited in clinical practice due
to the risk of fatal agranulocytosis and requirement for
neutrophil count monitoring. Only one Class II study [115]
demonstrated that quetiapine possibly improved PD psy-
chosis. Olanzapine failed to improve psychosis and worsened
parkinsonism [116, 117]. As such, the Practice Parameter
authors recommended that clozapine could be considered
as Level B and quetiapine, as Level C treatments, for PD
psychosis [118]. The conclusions from the AAN Practice
Parameter underscore the need to identify novel compounds
thataresafeandeﬀectiveinreducingpsychosiswithoutcom-
promising motor function. Furthermore, these agents will
require evaluation in well-designed, randomized, controlled
trials in order to withstand rigorous methodological review
and meet criteria for evidence-based medicine. Two double-
blind, placebo-controlled studies, subsequently published
and thus not included in the AAN review, have failed to
demonstrate signiﬁcant improvement with quetiapine in
ratings of psychosis although parkinsonism did not worsen
[119, 120]. The quetiapine studies, however, have been crit-
icized for methodological issues, such as poor recruitment,
patient populations with mixed diagnoses (some with PD,
PD and dementia, dementia with Lewy bodies, or Alzheimer
disease with parkinsonism), low doses of medications,
selection of psychosis rating scales or primary outcomes, and
small sample sizes. Recruitment for PD psychosis clinical
trials remains a challenging issue; inﬂuential factors include
the widespread clinical use of quetiapine despite negative
double-blind, placebo-controlled trial results; patient and
caregiverconcernsaboutplaceboassignmentespeciallywhen
hallucinations are frightening and delusions are present;
risk of worsened motor function; and recent “black box”
warnings by the FDA regarding increased risk of death
in elderly patients with dementia who received treatment
with antipsychotics. These important issues also must be
addressed in trials for PD psychosis.
7. Conclusions andFutureDirections
Although the dopaminergic system remains important in
the pathogenesis of psychosis in PD, new research strategies
shouldconsider the complex relationships among other neu-
rochemical and neuroanatomical substrates and potentially
integrate these elements into targets for drug development.
Similarly, investigations of PD psychosis should examine the
inﬂuences of other neuropsychiatric features of PD such
as attention, cognition, sleep, and mood. Alterations in
visualand cognitive processing may provide usefultargets, as
deﬁcits span from the retina to brainstem to cortical regions.
While the optimal treatment of PD psychosis remains a chal-
lenge, integrating studies of neuroimaging and genetic sus-
ceptibility,andperhaps,animalmodelsmaypermitadvances
in drug development. Examination of clinical and genetic
factors of those PD patients who never hallucinate despite
highdopaminergicmedicationdosesmayalsoprovideuseful
information on protective mechanisms and strategies.
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